von Roemeling R - Department of Medicine, University of Minnesota

基本信息

浏览量：7

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 57 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

P1121: TAKEAIM LYMPHOMA- AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION TRIAL OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES

E. Joffe,G. Nowakowski,H. Tun,A. Rosenthal,M. Lunning,R. Ramchandren,C.-C. Li, L. Zhou, E. Martinez,R. von Roemeling, R. Earhart, M. McMahon,I. Isufi,L. Leslie

HemaSphere (2022): 1011-1012

引用0浏览0引用

S129: TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS

G. Garcia-Manero,E. S. Winer,D. J. DeAngelo, S. Tarantolo,D. A. Sallman,J. Dugan,S. Groepper,A. Giagounidis,K. Götze,K. H. Metzeler, C.-C. Li, L. Zhou,E. Martinez,M. Lane,R. von Roemeling, M. Bohme,A. S. Kubasch,A. Verma,U. Platzbecker

HemaSphere（2022）

引用10浏览0引用

P473: development of potential biomarkers for irak4 inhibitor emavusertib in human acute myeloid leukemia

A. Ugolkov,M. Pilichowska,C.-C. Li, R. C. Hok, M. Samson, M. Lane,R. Von Roemeling, R. Martell

HemaSphere (2022): 372-373

引用0浏览0引用

POS0416 PRECLINICAL EFFICACY OF AN OXAZOLOPYRIDINE IRAK4 INHIBITOR IN RODENT MODELS OF INFLAMMATION

A. Ugolkov,R. Von Roemeling, R. Martell

ANNALS OF THE RHEUMATIC DISEASES (2022): 463-463

引用0浏览0引用

AN OPEN‐LABEL TRIAL OF ORAL CA‐4948 AN IRAK4 INHIBITOR COMBINED WITH IBRUTINIB IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES

E. Joffe,R. Ramchandren,G. Nowakowski,A. Rosenthal,H. W. Tun,M. Lunning,M. D. Mead, E. Martinez,R. von Roemeling,L. Leslie

Hematological Oncologyno. S2 (2021)

引用1浏览0引用

A Randomized, Placebo-Controlled, Phase 2 Study of Efatutazone Maintenance Therapy in Patients with Advanced Colorectal Cancer Who Have Achieved Disease Control Following First-Line Chemotherapy

E. Boucher,I. Davidenko, D. Hadler,R. von Roemeling,G. Aprile

Annals of oncology（2014）

引用0浏览0引用

Efatutazone, an Oral PPAR-γ Agonist, in Combination with Paclitaxel in Anaplastic Thyroid Cancer: Results of a Multicenter Phase 1 Trial

R. C. Smallridge,J. A. Copland,M. S. Brose,J. T. Wadsworth,Y. Houvras,M. E. Menefee,K. C. Bible,M. H. Shah,A. W. Gramza,J. P. Klopper,L. A. Marlow,M. G. Heckman,R. Von Roemeling

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM（2013）

引用101浏览0WOS引用

101

Tivantinib (ARQ 197) vs Placebo in patients with Hepatocellular Carcinoma (HCC) who failed one systemic therapy: results of a randomized controlled phase 2 trial

F. T. Kolligs,J. Trojan,P. Buggisch, G. Gerken,R. M. Schmid,E. N. de Toni, S. Zeuzem,C. Porta,I Borbath,L. Rimassa,B. Daniele,S. Salvagni,J-L van Laethem,H. van Vlierberghe,A. Gasbarrini,M. Lencioni,R. von Roemeling,G. Abbadessa,B. Schwartz,A. Santoro

ONKOLOGIEno. SUPnan (2012): 162-163

引用0浏览0引用

Met As Prognostic Factor and Therapeutic Target in Pretreated Hepatocellular Carcinoma (HCC): Final Results of a Randomized Controlled Phase 2 Trial (RCT) with Tivantinib (ARQ 197)

B. Daniele,L. Rimassa,C. Porta,I. Borbath,S. Salvagni,J. van Laethem,H. van Vlierberghe,R. von Roemeling,G. Abbadessa,A. Santoro

Annals of Oncology（2012）

引用5浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn